Tesamorelin

Description

Tesamorelin is a stabilized GHRH analog in which the natural GHRH sequence is modified by a trans-3-hexenoyl group at position 1. This modification extends the half-life to approximately 30-40 minutes and makes the compound substantially more resistant to DPP-IV degradation than unmodified GHRH 1-44. Tesamorelin is one of the most clinically characterized GHRH analogs.

The research background lies in visceral fat metabolism. In original tesamorelin research, the compound was investigated in HIV-associated lipodystrophy research, with documented effects on the reduction of visceral adiposity. These studies (Falutz et al., NEJM 2007) are among the most well-documented clinical data on GHRH analog research.

Mechanistically, tesamorelin acts through GHRH receptors of the anterior pituitary and stimulates endogenous GH secretion. In contrast to exogenous HGH, the natural negative feedback regulation via IGF-1 is preserved, making the compound a more physiologically grounded research tool. Downstream IGF-1 increases are characterized in the literature as moderate.

In research setups, tesamorelin is typically applied daily subcutaneously, with effects on IGF-1 levels and visceral adiposity markers as primary endpoints.

Tesamorelin is available in 2mg vials as 10-vial packs.

This information is for research and educational purposes only. No medical recommendations.

Risks & Safety

Tesamorelin is considered well tolerated per study reports. As one of the most clinically characterized GHRH analogs, the compound has a substantial safety database from lipodystrophy research, with a largely mild profile.

Observed in research and user reports:

• Injection site: mild redness, pressure or transient irritation at the injection site is the most common observation with subcutaneous use.
• GH-typical effects: as is common with GH secretagogues, the literature describes transient water retention as well as numbness or tingling in the hands (carpal-tunnel-type symptoms), joint discomfort and muscle pain, usually dose-dependent and reversible.
• Glucose metabolism: elevated GH and IGF-1 levels can raise fasting blood glucose and reduce insulin sensitivity in studies - a point documented in the clinical Tesamorelin trials.
• Occasionally flushing, headache or brief fatigue shortly after application is reported.
• No long-term data: despite clinical studies up to 52 weeks, robust human studies over very long periods for research use do not exist.

This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.

Studies

• Effects of tesamorelin on visceral fat in HIV-infected patients - NEJM 2007: Falutz et al., phase 3 study over 26 weeks.
• Long-term safety and effects of tesamorelin - AIDS Journal 2011: 52-week longitudinal data.
• Effects of GHRH on visceral fat distribution - JCEM 2004: Mechanism study on the GHRH axis and fat distribution.